The "U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report by Stage Type (Preclinical, Clinical, Commercial), Customer Type, Therapeutic Area, Region, and Segment ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva announced today its intention to divest its active-pharmaceutical ingredient (API) business, or "TAPI". TAPI is a global leader in the small-molecule API ...

TEDA TIANJIN, China--(BUSINESS WIRE)-- Asymchem Laboratories (Tianjin) Co., Ltd. (Stock Code 002821.SZ/6821.HK) announced today that it will operate the former Pfizer U.K. small molecule API pilot ...

Teva announced its intention to divest its active-pharmaceutical ingredient business, or "TAPI". TAPI is a global leader in the small-molecule API industry, with approximately 4,300 employees ...

Teva (NYSE:TEVA) plans to divest its active-pharmaceutical ingredient (API) business as part of its Pivot to Growth strategy to focus on its core business strengths. "The intent to divest TAPI will ...

Machine-learning platform enables signal peptide-informed discovery of small molecules that selectively inhibit protein secretion allowing for the degradation of disease-related proteins at the point ...

Raubling, Germany-based Axplora, which focuses on small-molecule API manufacturing reports that its total investments initiated across its global network in 2025 will exceed €100 million ($115.6 ...

Teva’s transformation under new CEO Richard Francis is taking another turn. Wednesday, the company confirmed plans to sell its active pharmaceutical ingredients business as part of Francis’ “pivot to ...

Patients want pills. We see this in the GLP-1 space. Everything should actually be flowing money towards pills, because payers are also quicker to reward pills. Yet the money is going exactly in the ...